The Quiet Consolidation Happening in Wound Care
There is a restructuring underway in the wound care industry that most people inside it can feel but haven’t fully articulated yet. It’s showing up in acquisition announcements, in the silence where sales reps used to be, in AR ledgers that haven’t moved in months, and in manufacturers quietly shopping their portfolios to anyone with a term sheet. What looked like a shakeout a year ago is starting to look like something more permanent.
This is consolidation. And it’s moving faster than most people expected.
The Deals Tell Part of the Story
The transaction activity over the last 14 months has been notable. In January 2026, BioStem Technologies acquired the surgical and wound care business of BioTissue Holdings for an upfront cash payment of approximately $15 million, with potential milestone payments of up to $25 million additional.¹ The strategic logic was clear: BioStem said the acquisition would support its advancement into high-value adjacent market segments, from acute surgical wounds to burns and soft-tissue repair.² Critically, this was a move away from the physician office setting and toward the OR, a deliberate pivot by a company reading where the market is heading.
BioStem wasn’t alone. In November 2025, Solventum announced a definitive agreement to acquire Acera Surgical, a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in contingent payments.³ Solventum, which spun off from 3M in 2024, is building scale in advanced wound care with the kind of balance sheet most companies in this space can only look at from a distance.
Then there’s the quieter activity. In December 2025, New Horizon Medical Solutions announced the acquisition of Applied Tissue Technologies’ business assets, a 25-year-old wound care company based in Boston.⁴ Not a headline deal. Not a billion-dollar transaction. Just a smaller manufacturer getting absorbed into a larger portfolio, which is exactly how most of this consolidation is actually happening.
These deals are not isolated. They are symptoms of a market under structural pressure looking for a way to reorganize itself.
What Actually Broke the Market
To understand why consolidation is accelerating, you have to understand what happened to the underlying economics.
Medicare Part B spending on skin substitutes exploded from $252 million in 2019 to over $10 billion in 2024, a nearly 40-fold increase while patient volume only doubled.⁵ CMS noticed. The response was significant. On October 31, 2025, CMS released the final rule for the 2026 Medicare Physician Fee Schedule, moving skin substitutes out of individual biologic codes and into a single flat incident-to supply rate of approximately $127 per square centimeter per application, regardless of brand or product type.⁶
That single policy decision restructured the economics of an entire industry overnight.
Before the rule, products were being reimbursed at wildly divergent rates. Prices of skin substitutes varied by more than a factor of ten, with the average price being $5,089 per square inch.⁷ That kind of spread created room for enormous margin, which attracted capital, which attracted new entrants, which flooded the market with products that had no clinical evidence behind them and no real infrastructure around them. When the price floor collapsed, so did most of those business models.
What I watched happen in real time was brutal. Pricing that had been holding at $50 a unit dropped to $10 by the end of January. The companies that could sustain that kind of compression were the ones that owned their manufacturing outright. Everyone else started doing math they didn’t like.
Compounding the pricing pressure was something that doesn’t show up in any market report: the AR problem. When Medicare began auditing aggressively and reimbursement uncertainty took hold, a significant number of manufacturers ended up with tens of millions in outstanding receivables they couldn’t collect. Physicians were being audited, payments were clawed back or delayed, and the cash flow that was supposed to fund operations dried up faster than anyone anticipated. BioStem itself reported that net revenue for full year 2025 was $47.5 million, compared to $69.7 million for full year 2024, with the decline primarily driven by lower wound care volume resulting from reimbursement uncertainty and increased competition in the physician office and mobile settings.⁸
That revenue drop, from a company considered one of the stronger operators in this space, tells you something about how broadly the market contracted. Companies with weaker balance sheets didn’t just see revenue drop. They saw their ability to survive the next quarter come into question.
The Manufacturing Question Is the Whole Game
Here’s what the acquisition activity is really sorting out: who actually owns their manufacturing and who doesn’t.
There is a category of company in this industry that holds a Q code, contracts with a third-party processor to make the product, and then markets and distributes it under their own label. That model worked when reimbursement was generous and margins were thick enough to cover licensing fees, royalties, and distribution overhead. It does not work at $127 per centimeter with a flat rate applied uniformly across every product in the category.
The only companies structurally capable of surviving the new pricing environment are those who manufacture in-house, carry no licensing burden, and can bring cost down far enough to compete at the floor. CMS has made clear it is betting that market competition under a single price point will drive down prices for most skin substitute products while preserving access to clinically appropriate treatments.⁹ That bet rewards vertical integration and punishes everyone else.
There’s a second survival path, and it runs through the hospital. Companies with GPO contracts, OR presence, and the ability to sell into hospital-based wound centers are insulated from the physician office pricing collapse in ways that pure physician-office players simply are not. The new payment structure is expected to shift more wound care volume back into hospital-based settings.¹⁰ The companies that anticipated this and built those relationships before the rule went into effect are now in a fundamentally different competitive position than those who didn’t.
The third survival profile is the diversified manufacturer, meaning a company that has other facets of its business requiring the same processing infrastructure as wound care products. Those companies can absorb the margin compression in wound care because they’re spreading fixed manufacturing costs across a broader revenue base. They can hold the line on pricing longer than a pure-play wound care manufacturer whose entire cost structure depends on product margin in a single category.
Everyone else is either a target or a cautionary tale.
Caught Off Guard
What made the current environment more damaging than it needed to be is that a significant number of companies simply did not believe the market would move this decisively. The delays, the executive order freezing the LCDs in early 2025, the political back-and-forth around implementation, all of it created a false sense that the regulatory pressure would soften or stall long enough for the industry to adjust. On December 24, 2025, CMS issued a press release stating that the MACs were withdrawing the Local Coverage Determinations for skin substitute grafts that were scheduled to become effective January 1, 2026.¹¹ But withdrawal didn’t mean the pressure went away. The incident-to reclassification and the $127 price cap moved forward regardless.
Companies that used the delay period to get compliant, restructure their product portfolios, and build evidence-based positioning came out of 2025 in reasonable shape. Companies that used the delay period to keep operating the old model without making structural changes came out of 2025 with cash flow problems, unresolved AR, and a shrinking market for their products.
That distinction, between companies that adapted and companies that waited, is one of the primary drivers of the M&A activity we’re seeing now. Assets are available. Prices reflect distress. Buyers with capital and manufacturing infrastructure are moving.
What the Market Looks Like on the Other Side
My honest read on where this ends is a market that looks almost unrecognizable compared to where it was in 2022 or 2023.
The field will likely consolidate to somewhere around nine or ten meaningful companies. Not the dozens of Q code holders and resellers that flooded the space during the high-reimbursement years. Real manufacturers, with real infrastructure, real evidence, and real relationships with the payers and systems that control access to patients.
The way end users interact with those companies will be different too. The rep-heavy, relationship-driven, logistics-intensive support model that characterized physician office wound care is not coming back at scale. What replaces it will be more streamlined, more hospital-centric, and more dependent on GPO relationships and clinical evidence than on field presence alone.
The new CMS rule marks a turning point in how wound care is delivered, documented, and reimbursed.¹² That’s accurate. But it’s also a turning point in who gets to deliver it at all.
The companies being acquired right now are not failures. Many of them built real products and served real patients. But they were built for a market that no longer exists, and the capital that sustained them has moved on to platforms that are structured for what’s coming next.
At Bionavix, we’ve been watching this closely and working through what it means for the physicians and partners we support. The consolidation doesn’t change the fundamentals of what good wound care looks like. It changes who’s in the room when it gets delivered, and how those relationships need to be structured going forward.
The quiet part of all this is that the restructuring isn’t finished. There are more deals coming. More portfolios going to market. More companies that will look at their balance sheets in Q2 and Q3 and decide that finding the right acquirer is a better outcome than trying to survive another year of margin compression in a market that has permanently repriced.
The companies that understand that early will make better decisions. The ones that don’t will be on the wrong end of the next announcement.
Sources
¹ BioSpace. “BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business.” January 22, 2026.
² Medical Device Network. “BioStem Acquires BioTissue’s Surgical and Wound Care Assets in $40M Deal.” January 23, 2026.
³ Solventum Investor Relations. “Solventum Announces Agreement to Acquire Acera Surgical.” November 20, 2025.
⁴ Morningstar / AccessWire. “New Horizon Medical Solutions Announces the Acquisition of the Applied Tissue Technologies Business Assets.” December 29, 2025.
⁵ HCH Lawyers. “CMS Fundamentally Restructures Skin Substitute Payments for 2026.” December 2025.
⁶ Wound Care Advantage. “Medicare’s 2026 Rule Shakes Up Wound Care Payments.” October 2025.
⁷ Parents Guide Cord Blood. “Countdown to Changes in Payments for Placenta Wound Dressings.” 2025.
⁸ BioSpace. “BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results.” March 24, 2026.
⁹ HCH Lawyers. “CMS Fundamentally Restructures Skin Substitute Payments for 2026.” December 2025.
¹⁰ Wound Care Advantage. “Medicare’s 2026 Rule Shakes Up Wound Care Payments.” October 2025.
¹¹ HMP Global Learning Network. “Medicare Part B MACs Withdraw Skin Substitute LCDs.” December 2025.
¹² Relias. “Navigating New CMS Skin Substitute Updates.” 2025.